<DOC>
	<DOCNO>NCT00541281</DOCNO>
	<brief_summary>propose randomize patient hormone resistant prostate cancer docetaxel/estramustine/prednisone docetaxel/prednisone phase II study . The principal endpoint efficacy term PSA response .</brief_summary>
	<brief_title>Safety Efficacy Study Docetaxel v Docetaxel Estramustine Hormone Refractory Prostatic Cancer</brief_title>
	<detailed_description>The addition estramustine chemotherapeutic agent affect microtubule function may improve efficacy15 , 16 , 17 , 18 . A phase III trial compare vinblastine versus combination vinblastine plus estramustine treatment patient hormone-refractory prostate cancer . They show association estramustine vinblastine superior vinblastine alone time progression , PSA response survival ( Hudes et al. , ASCO 2002 ) . In addition , Berry et al . find estramustine/paclitaxel improve PSA response rate overall survival compare paclitaxel alone ( Berry et al . ASCO2001 ) . Similar association study docetaxel . In phase I trial combine docetaxel estramustine19 , 53 % patient report decrease narcotic use 63 % experience PSA response . In another phase I trial , reduction PSA 50 % observe 14 17 patient ( 82 % ) 20 . In phase II trial involve 35 patient , PSA response report 74 % patient objective response 4 7 patient measurable disease21 . Median survival 22 month last study . These study well support combination estramustine docetaxel treatment HRPC22 , 23 . Recently , Oudard et al . compete phase II randomize study compare mitoxantrone/prednisone versus docetaxel/estramustine prednisone24 . Docetaxel give either weekly every 3 week . Association docetaxel/estramustine find superior mitoxantrone term PSA response , ( 67-63 % versus 18 % ) , clinical benefit ( 79-56 % versus 41 % ) survival ( 19.2 month versus 11.6 month ) . In addition , toxicity regimens manageable predictable . In study , patient receive 2 mgr coumadin prevent thromboembolic event due estramustine 7 % patient thrombosis . Other grade III &amp; IV toxicities estramustine/docetaxel combination include neutropenia ( 37 % 3-week regimen 0 % weekly regimen ) nausea/vomiting ( 2 % 3-week regimen 0 % weekly regimen ) , diarrhea ( 7 % 3-week regimen 0 % weekly regimen ) . No febrile neutropenia observe . Although data support role chemotherapy combination , estramustine docetaxel , treatment HRPC , study need determine relative contribution estramustine efficacy docetaxel/estramustine regimen . In context , propose randomize patient hormone resistant prostate cancer docetaxel/estramustine/prednisone docetaxel/prednisone phase II study . The principal endpoint efficacy term PSA response . We choose use weekly regimen describe Oudard since toxicity regimen well describe easily manageable experience .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms , Castration-Resistant</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Estramustine</mesh_term>
	<criteria>Signed informed consent prior begin protocol specific procedure . 18 year Histologically/cytologically proven prostate adenocarcinoma . Documented metastatic prostate adenocarcinoma Patients must receive prior hormonal therapy define : Castration orchiectomy and/or LHRH agonist without Antiandrogens Other hormonal agent ( e.g. , ketoconazole , ... ) Testosterone level &lt; 50 ng/dl patient ( castrate level ) . Respect antiandrogen withdrawal period No prior chemotherapy regimen exception estramustine phosphate . documented disease progression define either ( ) PSA increase and/or ( ii ) imaging : Prior radiation therapy ( less equal 25 % bone marrow ) allow . At least 4 week must elapse since completion radiation therapy patient must recover side effect . Prior surgery allow . At least 4 week must elapse since completion surgery . Life expectancy &gt; 3 month . ECOG performance status 02 . Normal cardiac function . Prior chemotherapy except estramustine phosphate . ( 2 ) Prior isotope therapy Prior radiotherapy &gt; 25 % bone marrow Prior malignancy except follow : adequately treat basal cell squamous cell skin cancer , cancer patient diseasefree &gt; 5 year . Known brain leptomeningeal involvement . Symptomatic peripheral neuropathy &gt; grade 2 Other serious illness medical condition Concurrent treatment experimental drug . Treatment anticancer therapy ( except LHRH agonist ) Treatment systemic corticosteroid use reason specify protocol must stop prior administration docetaxel .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>hormone resistant</keyword>
	<keyword>metastatic</keyword>
	<keyword>estramustine combine docetaxel</keyword>
	<keyword>randomize study</keyword>
</DOC>